Transaction · 0001567160-26-000011

Gano Kyle

Gano Kyle, CEO, reported a transaction classified as exercise at NEUROCRINE BIOSCIENCES INC involving 614.000000 shares for an estimated $0.00. Reported holdings after the transaction were 1228.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

exerciseSEC transaction code MCEO
NBIXNEUROCRINE BIOSCIENCES INC
Trade date
Nov 01, 2026
Filing date
Nov 03, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded614$0.00 per share
Holdings after1.22kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

NBIX price since this filing

Daily closing prices, with the filing date and available return windows
NBIX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -1.6%1w ago -1.9%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
exercise
Code M
Identifier
0001567160-26-000011
Restricted Stock Unit
Transaction date
Nov 01, 2026
Filed Nov 03, 2026, 10:59 PM · 2d delay
Shares
614 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
1,228 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Reduction
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.

  2. F2

    Each RSU represents a contingent right to receive one share of the Issuer's common stock.

  3. F3

    This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, vested as to 614 shares on November 1,…

Original filing · 0001567160-26-000011
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

NBIX